<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Zucman-Rossi, Jessica</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Use of Molecular Biology for Identifying Benign Hepatocellular Tumors Leads to More Personalized Medicine</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-8</style></pages><abstract><style  face="normal" font="default" size="100%">Benign hepatocellular adenomas are not a uniform liver disease but include different types of tumors, which can be classified as hemangioma (nonepithelial), focal nodular hyperplasia, and hepatocellular adenoma, the latter 2 being epithelial tumors. This article discusses how insights from molecular biology have profoundly changed our clinical understanding of benign liver tumors and how using the genotype-phenotype classification of these tumors can identify new etiologies, as well as diagnostic and prognostic features of this disease.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>